Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Volpe

Showing results (31-40 of 820) with videos related to

Pageof 82
Sort By:
European Heart Journal|February 22, 2021
Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factorLeonarda Galiuto, Massimo Volpe
European Heart Journal|September 19, 2025
Weekly Journal Scan: a real-world study in China shows that a tight control of blood pressure reduces all-cause dementiaGiovanna Gallo, Massimo Volpe
European Heart Journal|August 18, 2022
One-shot thrombolysis for the management of acute ischaemic strokeMassimo Volpe, Carlo Patrono
European Cardiology|May 19, 2020
Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?Allegra Battistoni, Massimo Volpe
European Heart Journal|June 25, 2022
The UK TAVI trial: an independent, pragmatic study extending the evidence for the treatment of symptomatic severe aortic stenosisRocco Vergallo, Massimo Volpe
European Heart Journal|January 13, 2023
Influenza vaccine for heart failure patients in low- and middle-income countries: another piece in the puzzleDaniela Pedicino, Massimo Volpe
European Heart Journal|June 21, 2021
The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low riskMassimo Volpe, Carlo Patrono
Current Medical Research and Opinion|July 22, 2004
Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician surveyMassimo Volpe, Elizabeth Machado
Journal of Hypertension|October 2, 2014
High natriuretic peptide levels and low DBP: companion markers of cardiovascular risk?Speranza Rubattu, Massimo Volpe
Advances in Therapy|December 29, 2018
Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of OlmesartanStefano Omboni, Massimo Volpe
Pageof 82

Showing results (31-40 of 820) with videos related to

Sort By:
Pageof 82
European Heart Journal|February 22, 2021
Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factorLeonarda Galiuto, Massimo Volpe
European Heart Journal|September 19, 2025
Weekly Journal Scan: a real-world study in China shows that a tight control of blood pressure reduces all-cause dementiaGiovanna Gallo, Massimo Volpe
European Heart Journal|August 18, 2022
One-shot thrombolysis for the management of acute ischaemic strokeMassimo Volpe, Carlo Patrono
European Cardiology|May 19, 2020
Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?Allegra Battistoni, Massimo Volpe
European Heart Journal|June 25, 2022
The UK TAVI trial: an independent, pragmatic study extending the evidence for the treatment of symptomatic severe aortic stenosisRocco Vergallo, Massimo Volpe
European Heart Journal|January 13, 2023
Influenza vaccine for heart failure patients in low- and middle-income countries: another piece in the puzzleDaniela Pedicino, Massimo Volpe
European Heart Journal|June 21, 2021
The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low riskMassimo Volpe, Carlo Patrono
Current Medical Research and Opinion|July 22, 2004
Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician surveyMassimo Volpe, Elizabeth Machado
Journal of Hypertension|October 2, 2014
High natriuretic peptide levels and low DBP: companion markers of cardiovascular risk?Speranza Rubattu, Massimo Volpe
Advances in Therapy|December 29, 2018
Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of OlmesartanStefano Omboni, Massimo Volpe
Pageof 82